Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.

Antimicrob Agents Chemother 2016 06 23;60(6):3669-75. Epub 2016 May 23.

Medicines for Malaria Venture, Geneva, Switzerland

Effective progression of candidate antimalarials is dependent on optimal dosing in clinical studies, which is determined by a sound understanding of pharmacokinetics and pharmacodynamics (PK/PD). Recently, two important translational models for antimalarials have been developed: the NOD/SCID/IL2Rγ(-/-) (NSG) model, whereby mice are engrafted with noninfected and Plasmodium falciparum-infected human erythrocytes, and the induced blood-stage malaria (IBSM) model in human volunteers. The antimalarial mefloquine was used to directly measure the PK/PD in both models, which were compared to previously published trial data for malaria patients. The clinical part was a single-center, controlled study using a blood-stage Plasmodium falciparum challenge inoculum in volunteers to characterize the effectiveness of mefloquine against early malaria. The study was conducted in three cohorts (n = 8 each) using different doses of mefloquine. The characteristic delay in onset of action of about 24 h was seen in both NSG and IBSM systems. In vivo 50% inhibitory concentrations (IC50s) were estimated at 2.0 μg/ml and 1.8 μg/ml in the NSG and IBSM models, respectively, aligning with 1.8 μg/ml reported previously for patients. In the IBSM model, the parasite reduction ratios were 157 and 195 for the 10- and 15-mg/kg doses, within the range of previously reported clinical data for patients but significantly lower than observed in the mouse model. Linking mouse and human challenge models to clinical trial data can accelerate the accrual of critical data on antimalarial drug activity. Such data can guide large clinical trials required for development of urgently needed novel antimalarial combinations. (This trial was registered at the Australian New Zealand Clinical Trials Registry [http://anzctr.org.au] under registration number ACTRN12612000323820.).

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.02883-15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879391PMC
June 2016
136 Reads
12 Citations
4.480 Impact Factor

Publication Analysis

Top Keywords

plasmodium falciparum
8
antimalarial drug
8
falciparum challenge
8
clinical trials
8
challenge models
8
trial data
8
ibsm model
8
nsg ibsm
8
clinical
6
models
5
data
5
50% inhibitory
4
concentrations ic50s
4
inhibitory concentrations
4
systems vivo
4
action nsg
4
ibsm systems
4
vivo 50%
4
μg/ml nsg
4
reported patients
4

Similar Publications